These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2516486)

  • 21. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
    Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [89Sr Therapy for pain relief in patients with bone metastases].
    Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
    Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Internal strontium-89 radiotherapy for malignant bony metastasis].
    Lou C; Zhang D; Yu L
    Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):507-9. PubMed ID: 11859724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematologic depression following therapy with strontium-89 chloride.
    Cowan RJ; Chilton HM; Cooper MR; Ferree CR; Watson EE; Robinson RG
    Clin Nucl Med; 1986 Dec; 11(12):845-6. PubMed ID: 2434277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
    Flamm J; Burkert S
    Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
    Altman GB; Lee CA
    Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Strontium chloride (89Sr-chloride) fractional injection method for bone metastases treatment].
    Fomin DK; Smirnov IuN; Tararukhina OB; Nazarov AA
    Vopr Onkol; 2012; 58(1):116-8. PubMed ID: 22629840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer].
    Zhao W; Deng H; Jie P; Qing C; Zhang X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1251-4. PubMed ID: 21374974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
    Wu YG; Ma QL; Liu GF
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):277-8. PubMed ID: 12575316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of symptomatic bone metastases of prostatic carcinoma using strontium chloride (Sr-89)].
    Dormia E; Mantovani F; Minervini S; Malagola G; Castellani R; Dormia G; Gonnella G; Mazza L; Luongo P; Bertana F
    Arch Ital Urol Androl; 1993 Apr; 65(2):161-6. PubMed ID: 8330061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Imaging of strontium-89 uptake with bremsstrahlung using NaI scintillation camera].
    Narita H; Uchiyama M; Ooshita T; Hirase K; Makino M; Mori Y; Sekine H; Kawakami K
    Kaku Igaku; 1996 Nov; 33(11):1207-12. PubMed ID: 8986059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [2 years of experience with 89Sr therapy of multiple bone metastases (author's transl)].
    Correns HJ; Mitterlechner E; Buchali K; Schnorr D; Seidel C; Mebel M
    Radiobiol Radiother (Berl); 1979 Jun; 20(3):360-2. PubMed ID: 515396
    [No Abstract]   [Full Text] [Related]  

  • 35. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate.
    Paszkowski AL; Hewitt DJ; Taylor A
    Clin Nucl Med; 1999 Nov; 24(11):852-4. PubMed ID: 10551466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
    Laing AH; Ackery DM; Bayly RJ; Buchanan RB; Lewington VJ; McEwan AJ; Macleod PM; Zivanovic MA
    Br J Radiol; 1991 Sep; 64(765):816-22. PubMed ID: 1717094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement standards for strontium-89 for use in bone palliation.
    Coursey BM; Schima FJ; Golas DB; Palabrica OT; Suzuki A; Dell MA
    Appl Radiat Isot; 1998 Apr; 49(4):335-44. PubMed ID: 9519442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.